157 related articles for article (PubMed ID: 23090696)
1. Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
Bauerschlag D; Bräutigam K; Moll R; Sehouli J; Mustea A; Salehin D; Krajewska M; Reed JC; Maass N; Hampton GM; Meinhold-Heerlein I
J Cancer Res Clin Oncol; 2013 Feb; 139(2):347-55. PubMed ID: 23090696
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
[TBL] [Abstract][Full Text] [Related]
3. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
[TBL] [Abstract][Full Text] [Related]
4. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
6. Differential gene expression analysis of ovarian cancer in a population isolate.
Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP
Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569
[TBL] [Abstract][Full Text] [Related]
7. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
8. Differential gene expression in ovarian carcinoma: identification of potential biomarkers.
Hibbs K; Skubitz KM; Pambuccian SE; Casey RC; Burleson KM; Oegema TR; Thiele JJ; Grindle SM; Bliss RL; Skubitz AP
Am J Pathol; 2004 Aug; 165(2):397-414. PubMed ID: 15277215
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary.
Lee CH; Subramanian S; Beck AH; Espinosa I; Senz J; Zhu SX; Huntsman D; van de Rijn M; Gilks CB
PLoS One; 2009 Oct; 4(10):e7314. PubMed ID: 19798417
[TBL] [Abstract][Full Text] [Related]
11. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
13. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I; Bauerschlag D; Zhou Y; Sapinoso LM; Ching K; Frierson H; Bräutigam K; Sehouli J; Stickeler E; Könsgen D; Hilpert F; von Kaisenberg CS; Pfisterer J; Bauknecht T; Jonat W; Arnold N; Hampton GM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):458-66. PubMed ID: 17255266
[TBL] [Abstract][Full Text] [Related]
14. Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.
Motamed-Khorasani A; Jurisica I; Letarte M; Shaw PA; Parkes RK; Zhang X; Evangelou A; Rosen B; Murphy KJ; Brown TJ
Oncogene; 2007 Jan; 26(2):198-214. PubMed ID: 16832351
[TBL] [Abstract][Full Text] [Related]
15. [Expression of mesothelin mRNA and protein in ovarian carcinomas].
Bi SN; Dai SZ; Yao Q; Che YC; Wang N
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):288-91. PubMed ID: 18788634
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
[TBL] [Abstract][Full Text] [Related]
18. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
19. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
[TBL] [Abstract][Full Text] [Related]
20. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]